Viatris - Monthly LongStock is in Monthly Demand Zone. Above $10 can make a good upmove.
Monthly Targets 15-21-31 Holding 2-12 Months for the targets.
LongCompare with Viatris Inc.
−0.35 USD
−3.51 B USD
14.29 B USD
1.13 B
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
Industry
CEO
Scott Andrew Smith
Website
Headquarters
Canonsburg
Founded
2019
IPO date
Feb 1, 1973
ISIN
US92556V1061
CUSIP
92556V106
FIGI
BBG00Y4RQNH4
Identifiers
ISIN US92556V1061
Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Maturity dateJun 15, 2046
Coupon5.25% (Fixed)
Maturity dateJun 22, 2050
Coupon4.00% (Fixed)
Maturity dateJun 22, 2040
Coupon3.85% (Fixed)
Maturity dateJun 22, 2030
Coupon2.70% (Fixed)
Maturity dateJun 22, 2027
Coupon2.30% (Fixed)
Maturity dateJun 17, 2033
Coupon4.25% (Fixed)
Maturity dateJun 23, 2032
Coupon1.91% (Fixed)
Maturity dateNov 22, 2028
Coupon3.13% (Fixed)
Maturity dateJun 23, 2027
Coupon1.36% (Fixed)
See all VTRS bonds
Frequently asked questions
The current price of VTRS is 16.12 USD — it has decreased by −0.98% in the past 24 hours. Watch Viatris Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Viatris Inc. stocks are traded under the ticker VTRS.
VTRS stock has fallen by −1.20% compared to the previous week, the month change is a −5.16% fall, over the last year Viatris Inc. has showed a 50.65% increase.
We've gathered analysts' opinions on Viatris Inc. future price: according to them, VTRS price has a max estimate of 23.00 USD and a min estimate of 12.00 USD. Watch VTRS chart and read a more detailed Viatris Inc. stock forecast: see what analysts think of Viatris Inc. and suggest that you do with its stocks.
VTRS reached its all-time high on Apr 24, 2015 with the price of 76.69 USD, and its all-time low was 0.04 USD and was reached on Mar 25, 1980. View more price dynamics on VTRS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
VTRS stock is 1.37% volatile and has beta coefficient of 0.58. Track Viatris Inc. stock price on the chart and check out the list of the most volatile stocks — is Viatris Inc. there?
Today Viatris Inc. has the market capitalization of 18.66 B, it has increased by 1.28% over the last week.
Yes, you can track Viatris Inc. financials in yearly and quarterly reports right on TradingView.
Viatris Inc. is going to release the next earnings report on Nov 9, 2026. Keep track of upcoming events with our Earnings Calendar.
VTRS earnings for the last quarter are 0.69 USD per share, whereas the estimation was 0.60 USD resulting in a 14.79% surprise. The estimated earnings for the next quarter are 0.65 USD per share. See more details about Viatris Inc. earnings.
Viatris Inc. revenue for the last quarter amounts to 3.76 B USD, despite the estimated figure of 3.68 B USD. In the next quarter, revenue is expected to reach 3.81 B USD.
VTRS net income for the last quarter is −118.80 M USD, while the quarter before that showed 176.40 M USD of net income which accounts for 0.00% change. Track more Viatris Inc. financial stats to get the full picture.
Yes, VTRS dividends are paid quarterly. The last dividend per share was 0.12 USD. As of today, Dividend Yield (TTM)% is 2.95%. Tracking Viatris Inc. dividends might help you take more informed decisions.
As of Aug 20, 2026, the company has 30 K employees. See our rating of the largest employees — is Viatris Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Viatris Inc. EBITDA is 4.23 B USD, and current EBITDA margin is 27.19%. See more stats in Viatris Inc. financial statements.
Like other stocks, VTRS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Viatris Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Viatris Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Viatris Inc. stock shows the buy signal. See more of Viatris Inc. technicals for a more comprehensive analysis.